Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study

Despite the emergence of various treatment strategies for rectal cancer based on neoadjuvant chemoradiotherapy, there is currently a lack of reliable biomarkers to determine which patients will respond well to neoadjuvant chemoradiotherapy. Through collecting hematological and biochemical parameters data of patients prior to receiving neoadjuvant chemoradiotherapy, we evaluated the predictive value of systemic inflammatory indices for pathological response and prognosis in rectal cancer patients. We found that baseline GRIm-Score was an independent predictor for MPR in rectal cancer patients. However, no association was observed between several commonly systemic inflammation indices and long-term outcome.

尽管基于新辅助放化疗（neoadjuvant chemoradiotherapy）的多种直肠癌治疗方案相继问世，但目前仍缺乏可靠的生物标志物（biomarkers）以甄别可从新辅助放化疗中获益的优势应答人群。本研究通过收集患者接受新辅助放化疗前的血液学与生化参数数据，评估了全身炎症指标对直肠癌患者病理应答与预后的预测价值。研究结果显示，基线GRIm-Score是直肠癌患者获得主要病理缓解（Major Pathological Response，MPR）的独立预测因子。然而，若干常用全身炎症指标与患者远期结局未观察到显著关联。